Indivior PLC
LSE:INDV
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
576.5
1 764
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one INDV stock under the Base Case scenario is 2 241.79 GBX. Compared to the current market price of 790 GBX, Indivior PLC is Undervalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Indivior PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for INDV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Indivior PLC
Balance Sheet Decomposition
Indivior PLC
Current Assets | 864m |
Cash & Short-Term Investments | 379m |
Receivables | 281m |
Other Current Assets | 204m |
Non-Current Assets | 671m |
Long-Term Investments | 26m |
PP&E | 107m |
Intangibles | 218m |
Other Non-Current Assets | 320m |
Current Liabilities | 1B |
Accounts Payable | 46m |
Accrued Liabilities | 761m |
Other Current Liabilities | 205m |
Non-Current Liabilities | 644m |
Long-Term Debt | 268m |
Other Non-Current Liabilities | 376m |
Earnings Waterfall
Indivior PLC
Revenue
|
1.1B
USD
|
Cost of Revenue
|
-195m
USD
|
Gross Profit
|
952m
USD
|
Operating Expenses
|
-688m
USD
|
Operating Income
|
264m
USD
|
Other Expenses
|
-405m
USD
|
Net Income
|
-141m
USD
|
Free Cash Flow Analysis
Indivior PLC
USD | |
Free Cash Flow | USD |
INDV Profitability Score
Profitability Due Diligence
Indivior PLC's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Indivior PLC's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
INDV Solvency Score
Solvency Due Diligence
Indivior PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Indivior PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INDV Price Targets Summary
Indivior PLC
According to Wall Street analysts, the average 1-year price target for INDV is 1 466.25 GBX with a low forecast of 1 262.5 GBX and a high forecast of 1 890 GBX.
Dividends
Current shareholder yield for INDV is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Slough, Berkshire and currently employs 802 full-time employees. The company went IPO on 2014-12-23. The firm is engaged in developing medicines to treat addiction and serious mental illnesses. The company focuses to build a portfolio of opioid dependence treatments. The company has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant and cannabis use disorders. Its pipeline products include INDV-3000 - Selective Dopamine D3-receptor Antagonist, RBP-6000 - Buprenorphine XR injection, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet and Buprenorphine Sublingual Tablet, among others. Its portfolio of products is available in more than 40 countries.
Officers
The intrinsic value of one INDV stock under the Base Case scenario is 2 241.79 GBX.
Compared to the current market price of 790 GBX, Indivior PLC is Undervalued by 65%.